Insecticides India Limited sees 30 technologies in 2-3 years

Insecticides India Limited said about 30 patented formulation technologies are expected to reach the market over the next two to three years, while management saw only one or two further launches in the remainder of FY27. The company therefore has a limited near-term launch calendar despite registrations in process for a much broader pipeline.

What launches are visible for IIL in FY27 and next fiscal?

IIL said no further major product launches were visible in the current fiscal, although management allowed for one or two odd launches during the remainder of FY27. Management said three to five launches were visible in the next fiscal, with registrations still in process for the wider pipeline. It did not provide revenue estimates for either the possible FY27 launches or the next-fiscal launches.

The immediate launch calendar is therefore smaller than the longer pipeline. IIL cited Spinoace and Granuvia as launches made during the current year, describing them as new technologies whose market response had been lukewarm because of low rain. Management expects some recovery in the second half through the rabi crop and a larger contribution next year, but did not quantify the expected sales contribution.

How will IIL use its 30-technology product pipeline?

IIL plans to bring about 30 patented formulation technologies to market over two to three years and may divide them between its existing business and Kaeros. Management said the volume of technologies in development was a reason for creating Kaeros as a parallel brand, because one company might not handle all of them efficiently. It did not disclose how many products each business would receive.

The pipeline includes a planned product with Nissan that management described as a new-mode-of-action herbicide for a major Indian requirement. IIL said it would assess the sales outcome after launch rather than attach a forecast beforehand. Nissan has been a partner since 2013, and management said IIL now handles seven Nissan products and expects to handle an eighth shortly, compared with two at the start of the relationship.

Kaeros provides a potential commercial route for some launches. Management said more than 55 Kaeros products had already reached the market and expected about 60 products during the current year. It also said more than 150 people had joined Kaeros in third-party and main-company roles, while its southern network was expected to be completed in the second half, creating an all-India network within the fiscal year.

How is IIL organizing research and development for new products?

IIL operates four research and development centres and generally books about Rs 12 crore of research and development expense, although management said the recorded figure understates the total work. Most centres are located within plants, which management said lowers the reported expense. Field trials are conducted by about a dozen doctors, but their cost is booked in marketing rather than research and development.

The research structure covers reverse engineering, formulations and new discovery. IIL said its Chopanki and Dahej, Gujarat, centres conduct reverse-engineering work, while formulation research is increasingly being conducted in Gujarat. Management said more than 100 registrations are involved in research and development at IIL, and about 200 people are involved directly and indirectly across IIL and its joint-venture research operation.

The new-discovery centre is a joint venture with a Japanese company that contributes 80% of its investment, while IIL contributes 20%. Management said this arrangement helps explain why booked research spending appears lower than the overall research effort. It did not disclose a future research-spending budget, but said it aims to conduct more research with lower reported expense.

When could IIL's OAT Agrio discovery molecule reach the market?

IIL said the first molecule from its OAT Agrio joint venture has a chance of reaching the market in the next fiscal year, subject to regulatory steps that management expects may take about one year from the call. Management had originally targeted a 2027 launch. It said an application to include the molecule in the first-product schedule of the Insecticide Act was awaiting clearance expected in a few months.

After schedule clearance, IIL plans to file its product application immediately, although management said its International Union of Pure and Applied Chemistry, or IUPAC, name registration was also pending. Management specifically said it did not expect to obtain registration by December because it anticipated a delay of a few months. The next-fiscal possibility is therefore conditional rather than a confirmed commercial launch date.

Management said it has visibility of at least three products from the joint venture. Once the first product process starts, IIL plans to begin data generation for the other products. The call did not disclose the molecules' crop uses, expected pricing, manufacturing location or prospective revenue, leaving regulatory timing as the principal near-term variable.

Conclusion

IIL's product outlook combines a sparse remainder of FY27, when only one or two further launches are possible, with a substantially larger plan for about 30 patented formulation technologies over two to three years. The three-to-five launches visible next fiscal, the planned Nissan herbicide and the possible first OAT Agrio molecule offer several routes to a broader portfolio, but management supplied no revenue contribution estimates.

The next items to watch are regulatory progress for the OAT Agrio molecule, including schedule clearance and the subsequent product application, and whether IIL delivers the three to five launches management sees next fiscal. Management also plans for Kaeros to reach about 60 products in the current year and complete its southern distribution network in the second half.